BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 30383447)

  • 1. Lack of acute xenogeneic graft- versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression.
    Brehm MA; Kenney LL; Wiles MV; Low BE; Tisch RM; Burzenski L; Mueller C; Greiner DL; Shultz LD
    FASEB J; 2019 Mar; 33(3):3137-3151. PubMed ID: 30383447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rγnull mice display a T-effector memory phenotype.
    Ali N; Flutter B; Sanchez Rodriguez R; Sharif-Paghaleh E; Barber LD; Lombardi G; Nestle FO
    PLoS One; 2012; 7(8):e44219. PubMed ID: 22937164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of novel major histocompatibility complex class I and class II-deficient NOD-SCID IL2R gamma chain knockout mice for modeling human xenogeneic graft-versus-host disease.
    Pino S; Brehm MA; Covassin-Barberis L; King M; Gott B; Chase TH; Wagner J; Burzenski L; Foreman O; Greiner DL; Shultz LD
    Methods Mol Biol; 2010; 602():105-17. PubMed ID: 20012395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human peripheral blood CD4 T cell-engrafted non-obese diabetic-scid IL2rγ(null) H2-Ab1 (tm1Gru) Tg (human leucocyte antigen D-related 4) mice: a mouse model of human allogeneic graft-versus-host disease.
    Covassin L; Laning J; Abdi R; Langevin DL; Phillips NE; Shultz LD; Brehm MA
    Clin Exp Immunol; 2011 Nov; 166(2):269-80. PubMed ID: 21985373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed onset of graft-versus-host disease in immunodeficent human leucocyte antigen-DQ8 transgenic, murine major histocompatibility complex class II-deficient mice repopulated by human peripheral blood mononuclear cells.
    Büchner SM; Sliva K; Bonig H; Völker I; Waibler Z; Kirberg J; Schnierle BS
    Clin Exp Immunol; 2013 Aug; 173(2):355-64. PubMed ID: 23607364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of Humanized Mice from Peripheral Blood Mononuclear Cells or Cord Blood CD34+ Hematopoietic Stem Cells for Immune-Oncology Studies Evaluating New Therapeutic Agents.
    Verma B; Wesa A
    Curr Protoc Pharmacol; 2020 Jun; 89(1):e77. PubMed ID: 32453514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engraftment of canine peripheral blood lymphocytes into nonobese diabetic-severe combined immune deficient IL-2R common gamma chain null mice.
    Foote JB; Kabir FM; Graff EC; Cattley RC; DeInnocentes P; Smith BF; Bird RC
    Vet Immunol Immunopathol; 2014 Feb; 157(3-4):131-41. PubMed ID: 24368085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human PBMC-transferred murine MHC class I/II-deficient NOG mice enable long-term evaluation of human immune responses.
    Yaguchi T; Kobayashi A; Inozume T; Morii K; Nagumo H; Nishio H; Iwata T; Ka Y; Katano I; Ito R; Ito M; Kawakami Y
    Cell Mol Immunol; 2018 Nov; 15(11):953-962. PubMed ID: 29151581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuation of graft-versus-host-disease in NOD scid IL-2Rγ(-/-) (NSG) mice by ex vivo modulation of human CD4(+) T cells.
    Hilger N; Glaser J; Müller C; Halbich C; Müller A; Schwertassek U; Lehmann J; Ruschpler P; Lange F; Boldt A; Stahl L; Sack U; Oelkrug C; Emmrich F; Fricke S
    Cytometry A; 2016 Sep; 89(9):803-15. PubMed ID: 27560708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human immune system development and survival of non-obese diabetic (NOD)-scid IL2rγ(null) (NSG) mice engrafted with human thymus and autologous haematopoietic stem cells.
    Covassin L; Jangalwe S; Jouvet N; Laning J; Burzenski L; Shultz LD; Brehm MA
    Clin Exp Immunol; 2013 Dec; 174(3):372-88. PubMed ID: 23869841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex.
    King MA; Covassin L; Brehm MA; Racki W; Pearson T; Leif J; Laning J; Fodor W; Foreman O; Burzenski L; Chase TH; Gott B; Rossini AA; Bortell R; Shultz LD; Greiner DL
    Clin Exp Immunol; 2009 Jul; 157(1):104-18. PubMed ID: 19659776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved engraftment of human peripheral blood mononuclear cells in NOG MHC double knockout mice generated using CRISPR/Cas9.
    Ka Y; Katano I; Nishinaka E; Welcker J; Mochizuki M; Kawai K; Goto M; Tomiyama K; Ogura T; Yamamoto T; Ito M; Ito R; Takahashi R
    Immunol Lett; 2021 Jan; 229():55-61. PubMed ID: 33253759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humanized Chronic Graft-versus-Host Disease in NOD-SCID il2rγ-/- (NSG) Mice with G-CSF-Mobilized Peripheral Blood Mononuclear Cells following Cyclophosphamide and Total Body Irradiation.
    Fujii H; Luo ZJ; Kim HJ; Newbigging S; Gassas A; Keating A; Egeler RM
    PLoS One; 2015; 10(7):e0133216. PubMed ID: 26176698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rejection of human islets and human HLA-A2.1 transgenic mouse islets by alloreactive human lymphocytes in immunodeficient NOD-scid and NOD-Rag1(null)Prf1(null) mice.
    Banuelos SJ; Shultz LD; Greiner DL; Burzenski LM; Gott B; Lyons BL; Rossini AA; Appel MC
    Clin Immunol; 2004 Sep; 112(3):273-83. PubMed ID: 15308121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Humanized Peripheral Blood Mononuclear Cell Mouse Model with Delayed Onset of Graft-versus-Host Disease for Preclinical HIV Research.
    Holguin L; Echavarria L; Burnett JC
    J Virol; 2022 Feb; 96(3):e0139421. PubMed ID: 34818071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased splenic human CD4
    Geraghty NJ; Belfiore L; Adhikary SR; Alexander SI; Sluyter R; Watson D
    Transpl Immunol; 2019 Jun; 54():38-46. PubMed ID: 30743002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced human CD4+ T cell engraftment in beta2-microglobulin-deficient NOD-scid mice.
    Christianson SW; Greiner DL; Hesselton RA; Leif JH; Wagar EJ; Schweitzer IB; Rajan TV; Gott B; Roopenian DC; Shultz LD
    J Immunol; 1997 Apr; 158(8):3578-86. PubMed ID: 9103418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Ry
    Burger DR; Parker Y; Guinta K; Lindner D
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):260-266. PubMed ID: 29128556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Xenogeneic Graft-Versus-Host Disease in Humanized NSG and NSG-HLA-A2/HHD Mice.
    Ehx G; Somja J; Warnatz HJ; Ritacco C; Hannon M; Delens L; Fransolet G; Delvenne P; Muller J; Beguin Y; Lehrach H; Belle L; Humblet-Baron S; Baron F
    Front Immunol; 2018; 9():1943. PubMed ID: 30214443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetically modified human CD4(+) T cells can be evaluated in vivo without lethal graft-versus-host disease.
    Ali R; Babad J; Follenzi A; Gebe JA; Brehm MA; Nepom GT; Shultz LD; Greiner DL; DiLorenzo TP
    Immunology; 2016 Aug; 148(4):339-51. PubMed ID: 27124592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.